Type 1 Diabetes Pipeline Outlook Report 2025: Breakthroughs in Research and Treatment Landscape

DelveInsight's, " Type 1 Diabetes Pipeline Insight, 2025 " report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Type 1 Diabetes Research. Learn more about our innovative pipeline today! @ Type 1 Diabetes Pipeline Outlook [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Type 1 Diabetes Pipeline Report

* On 10 September 2025, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) conducted a study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care.
* On 08 September 2025, Sanofi announced a study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.
* On 02 September 2025, Novo Nordisk A/S organized a study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
* DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
* The leading Type 1 Diabetes Companies such as Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
* Promising Type 1 Diabetes Pipeline Therapies such as Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016 and others.

Stay informed about the cutting-edge advancements in Type 1 Diabetes treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Type 1 Diabetes Clinical Trials Assessment [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Type 1 Diabetes Emerging Drugs Profile

* Insulin Efsitora Alfa: Eli Lilly and Company

LY3209590 ""Insulin Efsitora Alfa"" is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Type 1 Diabetes.

* Stem Cell Educator therapy: Throne Biotechnologies

Throne's Stem Cell Educator Therapy is designed to reverse the root causes of autoimmune diseases, such as diabetes and alopecia, by fundamentally "resetting" the immune system through a one-time dialysis-like treatment using CB-SC stem cells. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with Type 1 Diabetes.

* Frexalimab: Sanofi

Frexalimab (SAR441344) is a potentially first-in-class second generation investigational anti-CD40L antibody that blocks the costimulatory CD40/CD40L pathway which is important for activation and function of adaptive (T and B cells) and innate (macrophages/microglia and dendritic cells) immunity. Through this unique upstream mechanism of action, frexalimab has the potential to address both acute and chronic neuroinflammation in MS, without causing lymphocyte depletion. Sanofi is developing frexalimab under an exclusive license from ImmuNext. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Type 1 Diabetes.

* VX-880: Vertex Pharmaceuticals

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. It is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 is being investigated as an infusion into the hepatic portal vein and requires immunosuppressive therapy to protect the islet cells from immune rejection. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Type 1 Diabetes.

* MTX-101: Mozart Therapeutics

MTX-101 is a bispecific autoimmune checkpoint inhibitor. Its dual configuration binds the CD8 Treg receptors, KIR and CD8, to selectively activate CD8 Treg and enhance MTX-101's specificity, respectively. MTX-101 is designed to restore CD8 Treg functionality and the cytolytic elimination of pathogenic CD4 T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Type 1 Diabetes.

The Type 1 Diabetes Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
* Type 1 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.

Learn more about Type 1 Diabetes Drugs opportunities in our groundbreaking Type 1 Diabetes research and development projects @ Type 1 Diabetes Unmet Needs [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Type 1 Diabetes Companies

Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Type 1 Diabetes Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Discover the latest advancements in Type 1 Diabetes treatment by visiting our website. Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Type 1 Diabetes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Type 1 Diabetes Pipeline Report

* Coverage- Global
* Type 1 Diabetes Companies- Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
* Type 1 Diabetes Pipeline Therapies- Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016 and others.
* Type 1 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Type 1 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Type 1 Diabetes Pipeline on our website @ Type 1 Diabetes Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Type 1 Diabetes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Type 1 Diabetes- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Teplizumab: Provention Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TTP 399: Novo Nordisk
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SBP 101: Takeda Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Eflornithine oral: Panbela Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Type 1 Diabetes Key Companies
* Type 1 Diabetes Key Products
* Type 1 Diabetes- Unmet Needs
* Type 1 Diabetes- Market Drivers and Barriers
* Type 1 Diabetes- Future Perspectives and Conclusion
* Type 1 Diabetes Analyst Views
* Type 1 Diabetes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=type-1-diabetes-pipeline-outlook-report-2025-breakthroughs-in-research-and-treatment-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.